Literature DB >> 14724146

Effect of Helicobacter pylori eradication on treatment of gastro-oesophageal reflux disease: a double blind, placebo controlled, randomised trial.

J C Y Wu1, F K L Chan, J Y L Ching, W-K Leung, Y Hui, R Leong, S C S Chung, J J Y Sung.   

Abstract

BACKGROUND: The role of Helicobacter pylori eradication in the management of gastro-oesophageal reflux disease (GORD) is controversial. We hypothesised that H pylori eradication leads to worsened control of reflux disease.
METHODS: Consecutive patients with weekly reflux symptoms were prospectively recruited for endoscopy and symptom evaluation. Patients were enrolled if they had H pylori infection and required long term acid suppressants. Eligible patients were randomly assigned to omeprazole triple therapy (HpE group) or omeprazole with placebo antibiotics (Hp+ group) for one week. Omeprazole 20 mg daily was given for eight weeks for healing of oesophagitis and symptom relief. This was followed by a maintenance dose of 10 mg daily for up to 12 months. The primary study end point was the probability of treatment failure within 12 months, which was defined as either incomplete resolution of symptoms or oesophagitis at the initial treatment phase, or relapse of symptoms and oesophagitis during the maintenance phase. Predictors of treatment failure were determined by Cox's proportional hazards model.
RESULTS: A total of 236 GORD patients were screened and 113 (47.9%) were positive for H pylori; 104 (92%) patients were included in the intention to treat analysis (53 in the HpE group and 51 in the Hp+ group). Thirty one patients (30%) had erosive oesophagitis at baseline. H pylori was eradicated in 98% of the HpE group and in 3.9% of the Hp+ group. Overall, 15 patients (28.3%) in the HpE group and eight patients (15.7%) in the Hp+ group had treatment failure. The 12 month probability of treatment failure was 43.2% (95% confidence interval (CI) 29.9-56.5%) in the HpE group and 21.1% (95% CI 9.9-32.3%) in the Hp+ group (log rank test, p = 0.043). In the Cox proportional hazards model, after adjustment for the covariates age, sex, erosive oesophagitis, hiatus hernia, degree of gastritis, and severity of symptoms at baseline, H pylori eradication was the only predictor of treatment failure (adjusted hazard ratio 2.47 (95% CI 1.05-5.85)).
CONCLUSION: H pylori eradication leads to more resilient GORD.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14724146      PMCID: PMC1774911          DOI: 10.1136/gut.2003.012641

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  30 in total

1.  Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis.

Authors:  J Labenz; A L Blum; E Bayerdörffer; A Meining; M Stolte; G Börsch
Journal:  Gastroenterology       Date:  1997-05       Impact factor: 22.682

2.  Helicobacter pylori infection and chronic gastric acid hyposecretion.

Authors:  E M El-Omar; K Oien; A El-Nujumi; D Gillen; A Wirz; S Dahill; C Williams; J E Ardill; K E McColl
Journal:  Gastroenterology       Date:  1997-07       Impact factor: 22.682

Review 3.  Review article: Helicobacter pylori and gastro-oesophageal reflux disease-clinical implications and management.

Authors:  H J O'Connor
Journal:  Aliment Pharmacol Ther       Date:  1999-02       Impact factor: 8.171

4.  Helicobacter pylori infection potentiates the inhibition of gastric acid secretion by omeprazole.

Authors:  D Gillen; A A Wirz; W D Neithercut; J E Ardill; K E McColl
Journal:  Gut       Date:  1999-04       Impact factor: 23.059

5.  The incidence of reflux esophagitis among the Chinese.

Authors:  C S Chang; S K Poon; H C Lien; G H Chen
Journal:  Am J Gastroenterol       Date:  1997-04       Impact factor: 10.864

6.  Erosive esophagitis and Barrett's esophagus in Taiwan: a higher frequency than expected.

Authors:  C Yeh; C T Hsu; A S Ho; R E Sampliner; R Fass
Journal:  Dig Dis Sci       Date:  1997-04       Impact factor: 3.199

7.  Erosive oesophagitis: outcome of repeated long term maintenance treatment with low dose omeprazole 10 mg or placebo.

Authors:  K D Bardhan; P Cherian; A Vaishnavi; R B Jones; M Thompson; P Morris; A Brooks; J D'Silva; K R Gillon; C Wason; J Patterson; J Polak; A Bishop
Journal:  Gut       Date:  1998-10       Impact factor: 23.059

Review 8.  Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994.

Authors:  M F Dixon; R M Genta; J H Yardley; P Correa
Journal:  Am J Surg Pathol       Date:  1996-10       Impact factor: 6.394

9.  Omeprazole is more effective than cimetidine in the prevention of recurrence of GERD-associated heartburn and the occurrence of underlying oesophagitis.

Authors:  C M Bate; J R Green; A T Axon; G Tildesley; F E Murrays; S M Owen; C Emmas; M D Taylor
Journal:  Aliment Pharmacol Ther       Date:  1998-01       Impact factor: 8.171

10.  Rebound hypersecretion after omeprazole and its relation to on-treatment acid suppression and Helicobacter pylori status.

Authors:  D Gillen; A A Wirz; J E Ardill; K E McColl
Journal:  Gastroenterology       Date:  1999-02       Impact factor: 22.682

View more
  10 in total

Review 1.  Helicobacter pylori and oesophageal cancer--not always protective.

Authors:  Kenneth E L McColl
Journal:  Gut       Date:  2007-04       Impact factor: 23.059

Review 2.  The interplay between Helicobacter pylori, gastro-oesophageal reflux disease, and intestinal metaplasia.

Authors:  P Malfertheiner; U Peitz
Journal:  Gut       Date:  2005-03       Impact factor: 23.059

3.  Helicobacter pylori infection in patients with erosive esophagitis is associated with rapid heartburn relief and lack of relapse after treatment with pantoprazole.

Authors:  José L Calleja; Manuel Suarez; Alberto Herreros De Tejada; Angel Navarro
Journal:  Dig Dis Sci       Date:  2005-03       Impact factor: 3.199

Review 4.  Helicobacter pylori infection in children: an overview of diagnostic methods.

Authors:  Parisa Sabbagh; Mostafa Javanian; Veerendra Koppolu; VeneelaKrishna Rekha Vasigala; Soheil Ebrahimpour
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-02-07       Impact factor: 3.267

Review 5.  The spectrum of gastric disease associated with Helicobacter pylori and other infectious gastritides.

Authors:  Jeannette Guarner
Journal:  Curr Gastroenterol Rep       Date:  2004-12

6.  Eradication of Helicobacter Pylori Infections and GERD: A systematic review and meta-analysis.

Authors:  Wen-Ling Mou; Meng-Yao Feng; Li-Hua Hu
Journal:  Turk J Gastroenterol       Date:  2020-12       Impact factor: 1.852

7.  Alteration of correlation between serum pepsinogen concentrations and gastric acid secretion after H. pylori eradication.

Authors:  Katsunori Iijima; Tomoyuki Koike; Yasuhiko Abe; Nobuyuki Ara; Kaname Uno; Akira Imatani; Shuichi Ohara; Tooru Shimosegawa
Journal:  J Gastroenterol       Date:  2009-05-14       Impact factor: 7.527

Review 8.  Gastro-oesophageal reflux disease in Asia : birth of a 'new' disease?

Authors:  Ting K Cheung; Benjamin C Y Wong; Shiu K Lam
Journal:  Drugs       Date:  2008       Impact factor: 9.546

9.  Improvement of reflux symptom related quality of life after Helicobacter pylori eradication therapy.

Authors:  Kenro Hirata; Hidekazu Suzuki; Juntaro Matsuzaki; Tatsuhiro Masaoka; Yoshimasa Saito; Toshihiro Nishizawa; Eisuke Iwasaki; Seiichiro Fukuhara; Sawako Okada; Toshifumi Hibi
Journal:  J Clin Biochem Nutr       Date:  2013-03-01       Impact factor: 3.114

10.  A review of esomeprazole in the treatment of gastroesophageal reflux disease (GERD).

Authors:  Evangelos Kalaitzakis; Einar Björnsson
Journal:  Ther Clin Risk Manag       Date:  2007-08       Impact factor: 2.423

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.